

**UPDATE to the MEDSTAR FAMILY CHOICE FORMULARY  
District of Columbia - Healthy Families and Alliance Plans  
Changes for January 1, 2017**

**FORMULARY 2017 CHANGES**

Updates will continue to be available quarterly on this Website.

At the October 2016 Pharmacy and Therapeutics Committee meeting, the entire formulary was reviewed. At the November 2016 P&T meeting, additional modifications were made. The following is a summary of changes made for the MFC District of Columbia Healthy Families and Alliance 2017 Formularies:

Changes that will go into effect on January 1, 2017

Additions:

- Invokamet XR
- Cetaphil cleanser and bar
- Lidocaine cream 4%

Additions with Prior Authorization required:

- Albenza
- Bethkis Nebulizer Solution
- Epclusa
- Rasuvo
- Inflectra

Additions with Step Therapy requirements

- Ranexa has been added with a Step Therapy requirement: First must try and fail 30 days of a nitrate plus a beta blocker or calcium channel blocker in the past 365 days.

Removal of Prior Authorization:

- None

Step Therapy is no longer required for:

- CARMOL 10
- CARMOL 20
- Strattera
- Rizatriptan (tablets and ODT)
- Zolmitriptan (tablets and ODT)

Managed Drug Limitation changes:

- MDL on fluconazole has been increased from 3 per 23 days to 4 per 23 days

**Removals:\***

- **Sovaldi** (Epclusa was added to the formulary, Harvoni remains on formulary)
- **Relenza** (Tamiflu remains on formulary)
- **Tradjenta** (Januvia remains on formulary)
- **Jentadueto** (Janumet and Janumet XR will remain on formulary)
- **Cefixime** (multiple other 3<sup>rd</sup> generations cephalosporins remain on the formulary)

Details of the Prior Authorization Criteria are on this website in the Prior Authorization Table.

\* Members currently receiving medications that are being removed from the formulary will be grandfathered.

